Most surveyed individuals with obesity support lower-cost options for weight maintenance, which would allow better coverage for injectable incretin mimetics for weight management during active weight loss.
Dina H. Griauzde, MD, MSc, DABOM
Advertisement
Articles by Dina H. Griauzde, MD, MSc, DABOM
The high cost of incretin mimetics for weight management limits insurance coverage and potentiates variation in utilization management strategies to control near-term spending.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ebola Cases Top 1700 as Unpaid Health Workers Strike
2
FDA Approves Atacicept for IgA Nephropathy
3
340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs
4
Quest Adds Haystack MRD to OncoEMR for Community Oncology
5